Xu Chunfu's Modified Xianglian Pill Regulates the NOX2/ROS/Mitochondria/NLRP3 Axis to Treat Ulcerative Colitis.

Pharmaceuticals (Basel) · 2026 · PMC13029697 · PMID 41901297

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast to the normal group, the protein level profiles in the model group exhibited marked changes, whereas the high-dose XXLP group showed a trend toward partial reversion to the normal profile ( Figure 3 A).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.